Evidence map›Paper›PMID 38771750›Full record

ArticlePloS one2024

Reactive oxygen species in endothelial signaling in COVID-19: Protective role of the novel peptide PIP-2.

Oindrila Paul, Isha K Akolia, Jian Qin Tao, Nikita Jain, Natalia Louneva, Kathleen T Montone, Aron B Fisher, Chamith S Rajapakse, Christian Bermudez, Shampa Chatterjee

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Oindrila PaulInstitute for Environmental Medicine and Department of Physiology, Philadelphia, Pennsylvania, United States of America.
Isha K AkoliaInstitute for Environmental Medicine and Department of Physiology, Philadelphia, Pennsylvania, United States of America.
Jian Qin TaoInstitute for Environmental Medicine and Department of Physiology, Philadelphia, Pennsylvania, United States of America.
Nikita JainInstitute for Environmental Medicine and Department of Physiology, Philadelphia, Pennsylvania, United States of America.
Natalia LounevaPeroxitech Inc., Philadelphia, Pennsylvania, United States of America.
Kathleen T MontoneDepartment of Pathology, Philadelphia, Pennsylvania, United States of America.
Aron B FisherPeroxitech Inc., Philadelphia, Pennsylvania, United States of America.
Chamith S RajapakseDepartment of Radiology, Philadelphia, Pennsylvania, United States of America.
Christian BermudezDepartment of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America.
Shampa ChatterjeeInstitute for Environmental Medicine and Department of Physiology, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0003-3351-5580

Funding

The NLRP3 inflammasome in regulating injury with lung transplantR56HL139559 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHATTERJEE, SHAMPA · 2019 to 2019
$405k
An additive solution to expand the lung transplant organ poolR41HL164161 · NHLBI · PEROXITECH, LLC · PI CHATTERJEE, SHAMPA, FISHER, ARON B. · 2022 to 2022
$300k
NHLBI NIH HHS R41 HL164161NHLBI NIH HHS R56 HL139559
6 · The paper itself

Abstract

introductionRecent research suggests that endothelial activation plays a role in coronavirus disease 2019 (COVID-19) pathogenesis by promoting a pro-inflammatory state. However, the mechanism by which the endothelium is activated in COVID-19 remains unclear.

objectiveTo investigate the mechanism by which COVID-19 activates the pulmonary endothelium and drives pro-inflammatory phenotypes. HYPOTHESIS: The "inflammatory load or burden" (cytokine storm) of the systemic circulation activates endothelial NADPH oxidase 2 (NOX2) which leads to the production of reactive oxygen species (ROS) by the pulmonary endothelium. Endothelial ROS subsequently activates pro-inflammatory pathways.

methodsThe inflammatory burden of COVID-19 on the endothelial network, was recreated in vitro, by exposing human pulmonary microvascular endothelial cells (HPMVEC) to media supplemented with serum from COVID-19 affected individuals (sera were acquired from patients with COVID-19 infection that eventually died. Sera was isolated from blood collected at admission to the Intensive Care Unit of the Hospital of the University of Pennsylvania). Endothelial activation, inflammation and cell death were assessed in HPMVEC treated with serum either from patients with COVID-19 or from healthy individuals. Activation was monitored by measuring NOX2 activation (Rac1 translocation) and ROS production; inflammation (or appearance of a pro-inflammatory phenotype) was monitored by measuring the induction of moieties such as intercellular adhesion molecule (ICAM-1), P-selectin and the NLRP3 inflammasome; cell death was measured via SYTOX™ Green assays.

resultsEndothelial activation (i.e., NOX2 activation and subsequent ROS production) and cell death were significantly higher in the COVID-19 model than in healthy samples. When HPMVEC were pre-treated with the novel peptide PIP-2, which blocks NOX2 activation (via inhibition of Ca2+-independent phospholipase A2, aiPLA2), significant abrogation of ROS was observed. Endothelial inflammation and cell death were also significantly blunted.

conclusionsThe endothelium is activated during COVID-19 via cytokine storm-driven NOX2-ROS activation, which causes a pro-inflammatory phenotype. The concept of endothelial NOX2-ROS production as a unifying pathophysiological axis in COVID-19 raises the possibility of using PIP-2 to maintain vascular health.

Indexed as

COVID-19Endothelial CellsNADPH Oxidase 2Reactive Oxygen SpeciesSARS-CoV-2Signal TransductionEndothelium, VascularHumansIntercellular Adhesion Molecule-1LungPeptidesCYBB protein, humanIntercellular Adhesion Molecule-1NADPH Oxidase 2PeptidesReactive Oxygen Species

Identifiers

PMID38771750
PMCPMC11108150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.